Spinogenix Announces World Health Organization Approval of “Codabakalner” as International Nonproprietary Name for SPG601

Codabakalner is a First-in-Class Investigational Therapy Entering Phase 2b/3 Development for Fragile X Syndrome LOS ANGELES – July 16, 2026 – Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering novel therapeutics that have the potential to restore synapses to improve the lives of patients worldwide, today announced that the International Nonproprietary Names (INN) Expert Committee of…

Spinogenix Reports Positive Data on Alzheimer’s Patients Who Continued Treatment With Tazbentetol For Up To 84 Weeks

Tazbentetol, a First-in-Class, Oral Synaptic Regenerative Investigational Therapy, Demonstrated Favorable Safety Profile and Durable Therapeutic Benefits Clinical Case Study Presented at AAIC Highlights Caregiver Report of Rapid Cognitive Improvement with Supporting Clinical Outcome Measures Consistent with Durable Treatment Benefit Through 18 Months LOS ANGELES, July 14, 2026 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering…

Spinogenix Appoints Harvard Medical School Professor of Neurology Steven E. Arnold, MD, to Scientific Advisory Board

Appointment of Renowned Alzheimer’s Expert to Support Spinogenix’s Advancement of Neurodegenerative Disease Strategy and Translational Biomarker Development LOS ANGELES, July 9, 2026 – Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering novel therapeutics that have the potential to restore synapses to improve the lives of patients worldwide, today announced the appointment of Prof. Steven E. Arnold,…

Spinogenix Appoints Professor Joseph T. Coyle, MD, Current Chair of Psychiatry and Neuroscience at Harvard Medical School, to Scientific Advisory Board

Prof. Coyle to Provide Guidance on Company’s Neuroscience Pipeline, with Emphasis on Schizophrenia   LOS ANGELES, July 2, 2026 – Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering novel therapeutics that have the potential to restore synapses to improve the lives of patients worldwide, today announced the appointment of Prof. Joseph T. Coyle, MD, a globally recognized expert in psychiatry and neuroscience, to its Scientific…

Spinogenix Recognizes Dr. Craig Erickson following $17.25 Million Autism Research Grant to Cincinnati Children’s Hospital

Grant Will Support Spinogenix Chief Medical Advisor’s Research into Precision Medicine and EEG   LOS ANGELES, June 15, 2026 – Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering novel therapeutics that have the potential to restore synapses to improve the lives of patients worldwide,  today recognized Chief Medical Advisor, Craig Erickson, MD and Cincinnati Children’s Hospital for receiving a $17.25 million, five-year grant from…

Spinogenix to Present Preclinical Results at ARVO 2026 Demonstrating Neuroprotective Effects of Tazbentetol in Glaucoma and Diabetic Retinopathy Models

New Preclinical Data Show Tazbentetol Reduces Retinal Cell Loss and Preserves Visual Function in Glaucoma and Diabetic Retinopathy Models LOS ANGELES, May 3, 2026 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics designed to restore synapses to improve the lives of patients, will present this week the results of two new preclinical studies…

Spinogenix Announces CLARITY: a Phase 2b/3 trial of SPG601 for the Treatment of Fragile X Syndrome

LOS ANGELES, April 23, 2026 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics designed to restore synapses to improve the lives of patients, is initiating CLARITY, a Phase 2b/3 adaptive trial evaluating SPG601 in male patients with Fragile X Syndrome (FXS). SPG601 is a first-in-class, oral tablet designed to modulate the activity of…

New Peer-Reviewed Research Demonstrates Neurophysiological Efficacy of Spinogenix’s SPG601 in Patients with Fragile X Syndrome

Study Results, Published in Nature Scientific Reports, Found SPG601 Reduced Signature Changes in High-Frequency Gamma Band Activity and Improved Cognition in FXS Patients   LOS ANGELES, April 9, 2026 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced the publication of a…

Spinogenix Reports Early Improvements in Phase 2 Trial of Tazbentetol in Patients with Schizophrenia at the Schizophrenia International Research Society (SIRS) 2026 Annual Congress

First-in-Class Synaptic Regenerative Therapy Demonstrates Favorable Safety Profile and Early Potential to Improve Symptoms of Schizophrenia   LOS ANGELES, March 26, 2026 /PRNewswire/ — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced interim results from its Phase 2 trial evaluating tazbentetol (formerly SPG302) for the…